Last updated: 17 June 2024 at 4:18pm EST

Richard Wright Net Worth




The estimated Net Worth of Richard M. Wright is at least $3.38 Million dollars as of 3 June 2024. Richard Wright owns over 67,469 units of Celldex Therapeutics stock worth over $2,818,070 and over the last 8 years he sold CLDX stock worth over $0. In addition, he makes $563,171 as Senior Vice President and Chief Commercial Officer at Celldex Therapeutics.

Richard Wright CLDX stock SEC Form 4 insiders trading

Richard has made over 3 trades of the Celldex Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 67,469 units of CLDX stock worth $1,267,743 on 3 June 2024.

The largest trade he's ever made was exercising 67,469 units of Celldex Therapeutics stock on 3 June 2024 worth over $1,267,743. On average, Richard trades about 8,636 units every 106 days since 2016. As of 3 June 2024 he still owns at least 67,677 units of Celldex Therapeutics stock.

You can see the complete history of Richard Wright stock trades at the bottom of the page.





Richard Wright biography

Dr. Richard Wright Ph.D. serves as Senior Vice President, Chief Commercial Officer of the Company. Dr. Wright served as Vice President of Commercial Operations of Celldex from April 2012 to July 2015. From November 2010 to April 2012, Dr. Wright was Managing Director of Navigant Consulting, a global life sciences consulting practice. From September 2003 to October 2010, Dr. Wright held several senior leadership roles at Bristol-Myers Squibb including Senior Vice President of the U.S. ImmunoScience Division. Dr. Wright currently serves on the Scientific Advisory Board for the Seaver Foundation, a nonprofit organization supporting the Center for Autism Treatment and Research at Mount Sinai Hospital. Dr. Wright received his B.S. in Biological Sciences from Rutgers University and his M.S. and Ph.D. in Microbiology and Molecular Genetics from The University of Medicine and Dentistry of New Jersey (Rutgers University). He received an M.B.A. in Marketing and Finance from Columbia University.

What is the salary of Richard Wright?

As the Senior Vice President and Chief Commercial Officer of Celldex Therapeutics, the total compensation of Richard Wright at Celldex Therapeutics is $563,171. There are 8 executives at Celldex Therapeutics getting paid more, with Ronald Pepin having the highest compensation of $1,225,030.



How old is Richard Wright?

Richard Wright is 56, he's been the Senior Vice President and Chief Commercial Officer of Celldex Therapeutics since 2015. There are 17 older and 7 younger executives at Celldex Therapeutics. The oldest executive at Celldex Therapeutics Inc. is Herbert Conrad, 87, who is the Independent Director.

What's Richard Wright's mailing address?

Richard's mailing address filed with the SEC is C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827.

Insiders trading at Celldex Therapeutics

Over the last 16 years, insiders at Celldex Therapeutics have traded over $19,527,314 worth of Celldex Therapeutics stock and bought 273,450 units worth $1,157,166 . The most active insiders traders include Rajesh B Parekh, Garry Arthur Neil, and Inc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of $1,750,671. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth $204,917.



What does Celldex Therapeutics do?

celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im



What does Celldex Therapeutics's logo look like?

Celldex Therapeutics Inc. logo

Complete history of Richard Wright stock trades at Celldex Therapeutics

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
3 Jun 2024 Richard M. Wright
SR. VP and CCO
Option 67,469 $18.79 $1,267,743
3 Jun 2024
67,677
15 Aug 2022 Richard M. Wright
SR. VP and CCO
Option 15,328 $10.38 $159,105
15 Aug 2022
15,536
14 Dec 2020 Richard M. Wright
SR. VP and CCO
Option 20,832 $6.21 $129,367
14 Dec 2020
9,583


Celldex Therapeutics executives and stock owners

Celldex Therapeutics executives and other stock owners filed with the SEC include: